Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_assertion type Assertion NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_head.
- NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_assertion description "[In contrast, in patients carrying both ligands, KIR2DS5 was associated with reduced LFS (p=0.0056; HR 0.3; 95% CI 0.1-0.7) and higher relapse rate (p=0.02; HR 0.35, 95% CI 0.1-0.8).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_provenance.
- NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_assertion evidence source_evidence_literature NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_provenance.
- NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_assertion SIO_000772 18555529 NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_provenance.
- NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_assertion wasDerivedFrom befree-20140225 NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_provenance.
- NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_assertion wasGeneratedBy ECO_0000203 NP405867.RAz4El5JXf6YW6qIOyApQCkrqQ-2gGOgD5JMQocJjgaaM130_provenance.